Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293206927> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4293206927 endingPage "15" @default.
- W4293206927 startingPage "10" @default.
- W4293206927 abstract "Immune checkpoint inhibitors (ICI) have revolutionized care in oncology with improved overall survival in several cancer populations. Nivolumab has recently been approved for use in patients with upper gastrointestinal cancers. We quantitatively summarized the efficacy and safety of Nivolumab use in patients with advanced esophageal, gastroesophageal, and gastric carcinoma compared to standard chemotherapy.Systemic search of electronic databases was performed to analyze phase III randomized controlled trials (RCTs) comparing Nivolumab versus standard chemotherapy in patients with advanced upper gastrointestinal cancers. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Data were pooled using random effects model via RevMan 5.4 software.Four RCTs with a total of 3369 patients and a median follow-up of 13 months were included. The patients' mean age was 61 ± 20 years, 74.6% were males, and 26% had ≥1% PD-L1 expression. Compared to the chemotherapy group, Nivolumab group had a significantly favorable OS and PFS [HR 0.81;95% CI (0.74, 0.89), p < .001], [HR 0.82;95% CI (0.69, 0.98), p = .03], respectively. Nivolumab significant effect was only in patients with ≥1% PD L1 expression [HR 0.72; 95% CI (0.58, 0.89), p < .001]. No statistical difference was detected between groups regarding serious adverse effects (AE) [OR 1.47; 95%CI (0.94,2.31), p = 0.09].Compared to standard chemotherapy, the use of Nivolumab in patients with advanced esophageal, gastroesophageal, and gastric cancers is associated with improved overall and progression-free survival, with similar rates of AE and AE leading to death. The improvement in survival was significant in patients with ≥1% PD L1 expression." @default.
- W4293206927 created "2022-08-27" @default.
- W4293206927 creator A5002414987 @default.
- W4293206927 creator A5028302677 @default.
- W4293206927 creator A5035109023 @default.
- W4293206927 creator A5040272772 @default.
- W4293206927 creator A5044358005 @default.
- W4293206927 creator A5050924701 @default.
- W4293206927 date "2022-09-07" @default.
- W4293206927 modified "2023-09-26" @default.
- W4293206927 title "Efficacy and safety of Nivolumab in patients with advanced esophageal, gastroesophageal, and gastric cancers: a meta-analysis of randomized controlled trials" @default.
- W4293206927 cites W2000894867 @default.
- W4293206927 cites W2590359520 @default.
- W4293206927 cites W2808524416 @default.
- W4293206927 cites W2976652879 @default.
- W4293206927 cites W2981790403 @default.
- W4293206927 cites W3012031682 @default.
- W4293206927 cites W3013311028 @default.
- W4293206927 cites W3047367404 @default.
- W4293206927 cites W3171517418 @default.
- W4293206927 cites W3195031262 @default.
- W4293206927 cites W3209848720 @default.
- W4293206927 cites W3214696739 @default.
- W4293206927 cites W3215253353 @default.
- W4293206927 cites W3216101837 @default.
- W4293206927 cites W4206384216 @default.
- W4293206927 cites W4207067024 @default.
- W4293206927 cites W4221134810 @default.
- W4293206927 cites W4226136872 @default.
- W4293206927 doi "https://doi.org/10.1080/08923973.2022.2117629" @default.
- W4293206927 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36017642" @default.
- W4293206927 hasPublicationYear "2022" @default.
- W4293206927 type Work @default.
- W4293206927 citedByCount "0" @default.
- W4293206927 crossrefType "journal-article" @default.
- W4293206927 hasAuthorship W4293206927A5002414987 @default.
- W4293206927 hasAuthorship W4293206927A5028302677 @default.
- W4293206927 hasAuthorship W4293206927A5035109023 @default.
- W4293206927 hasAuthorship W4293206927A5040272772 @default.
- W4293206927 hasAuthorship W4293206927A5044358005 @default.
- W4293206927 hasAuthorship W4293206927A5050924701 @default.
- W4293206927 hasBestOaLocation W42932069272 @default.
- W4293206927 hasConcept C121608353 @default.
- W4293206927 hasConcept C126322002 @default.
- W4293206927 hasConcept C143998085 @default.
- W4293206927 hasConcept C168563851 @default.
- W4293206927 hasConcept C197934379 @default.
- W4293206927 hasConcept C2776694085 @default.
- W4293206927 hasConcept C2777701055 @default.
- W4293206927 hasConcept C2779742542 @default.
- W4293206927 hasConcept C2780030458 @default.
- W4293206927 hasConcept C71924100 @default.
- W4293206927 hasConcept C90924648 @default.
- W4293206927 hasConceptScore W4293206927C121608353 @default.
- W4293206927 hasConceptScore W4293206927C126322002 @default.
- W4293206927 hasConceptScore W4293206927C143998085 @default.
- W4293206927 hasConceptScore W4293206927C168563851 @default.
- W4293206927 hasConceptScore W4293206927C197934379 @default.
- W4293206927 hasConceptScore W4293206927C2776694085 @default.
- W4293206927 hasConceptScore W4293206927C2777701055 @default.
- W4293206927 hasConceptScore W4293206927C2779742542 @default.
- W4293206927 hasConceptScore W4293206927C2780030458 @default.
- W4293206927 hasConceptScore W4293206927C71924100 @default.
- W4293206927 hasConceptScore W4293206927C90924648 @default.
- W4293206927 hasIssue "1" @default.
- W4293206927 hasLocation W42932069271 @default.
- W4293206927 hasLocation W42932069272 @default.
- W4293206927 hasLocation W42932069273 @default.
- W4293206927 hasOpenAccess W4293206927 @default.
- W4293206927 hasPrimaryLocation W42932069271 @default.
- W4293206927 hasRelatedWork W2040350626 @default.
- W4293206927 hasRelatedWork W2275543989 @default.
- W4293206927 hasRelatedWork W2353164399 @default.
- W4293206927 hasRelatedWork W2894730238 @default.
- W4293206927 hasRelatedWork W2948845624 @default.
- W4293206927 hasRelatedWork W2955084311 @default.
- W4293206927 hasRelatedWork W4256514411 @default.
- W4293206927 hasRelatedWork W4297216423 @default.
- W4293206927 hasRelatedWork W4307327611 @default.
- W4293206927 hasRelatedWork W4382344122 @default.
- W4293206927 hasVolume "45" @default.
- W4293206927 isParatext "false" @default.
- W4293206927 isRetracted "false" @default.
- W4293206927 workType "article" @default.